Announcement PDF ACRUX (ACR) - ASX ANNOUNCEMENT 28 JANUARY 2016 LAUNCH OF LENZETTO® IN EUROPEAN UNION Acrux (ASX: ACR) today announced that Lenzetto® has been launched in Poland and the Czech Republic. Lenzetto will be progressively rolled out in multiple additional European countries over coming months. Lenzetto® is Acrux’s estradiol spray for treating menopause symptoms that has been licensed exclusively in Europe to Gedeon Richter. Acrux’s estradiol product is branded Lenzetto® in Europe and Evamist® in the United States. For further information, contact Michael Kotsanis, CEO and Managing Director: 03 8379 0100 About Acrux Acrux (ASX: ACR) is a drug development company focused on commercialising topical products using its proprietary drug delivery technology. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and licensed a number of pharmaceutical products in the US and Europe using the Patchless PatchTM, a fast-drying and invisible topical application technology. Acrux will continue to innovate and bring its developed products to the market in collaboration with licensees. For further information on Acrux, visit www.acrux.com.au